Liezl Gambe

Austal (ASX:ASB) has been awarded a $1.03 billion design and build contract for landing craft medium vessels under the strategic shipbuilding agreement with Australia.

Aumake (ASX:AUK) has secured a Hong Kong pharmaceutical wholesale licence, paving the way for the company's expansion into China.

Verbrec (ASX:VBC), an engineering and mining technology services provider across Australia, New Zealand, Papua New Guinea.

Santos (ASX:STO) has confirmed that Fluor Australia has paid $1.07 billion following the Queensland Supreme Court’s ruling.

BetMakers Technology (ASX:BET) has signed a multi-year deal with online wagering operator Stake.

Woodside Energy (ASX:WDS) announced that CEO and Managing Director Meg O’Neill will step down to take on the role of CEO at BP, effective Dec. 28.

The Albanese government has cautiously agreed to provide about $10 billion in federal funding for Victoria's Suburban Rail Loop.

Nucor (NYSE:NUE) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting earnings per share (EPS) in the range of $1.65 to $1.75.

Jabil (NYSE:JBL) has reported preliminary, unaudited financial results for the first quarter of fiscal year 2026, posting strong performance with net revenue of $8.3 billion.

The company's U.S. GAAP operating income stood at $283 million, and U.S. GAAP diluted earnings per share (EPS) was $1.35.

Pfizer (NYSE:PFE) and Astellas have announced positive topline results from the interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial, evaluating the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).